Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women.
We investigated the 12-week effects of 3 doses of HMR 3339, a novel selective estrogen receptor modulator, in comparison with raloxifene and placebo, on plasma concentrations of C-reactive protein in 96 healthy postmenopausal women. A dose-dependent reduction in C-reactive protein was observed, the largest reduction with HMR 3339 50 mg.